Literature DB >> 10331602

FMRP expression as a potential prognostic indicator in fragile X syndrome.

F Tassone1, R J Hagerman, D N Iklé, P N Dyer, M Lampe, R Willemsen, B A Oostra, A K Taylor.   

Abstract

Absence or deficit of FMR1 protein (FMRP) resulting from methylation of full mutation genes is the fundamental defect in fragile X syndrome. We used FMRP immunocytochemistry and detailed phenotypic assessment to investigate the relationship between degree of FMRP expression and the broad clinical spectrum of impairment in 80 individuals affected with fragile X syndrome. FMRP expression correlated with IQ in mosaic males (P=0.043), males with a partially methylated full mutation (P=0.0005), and females with a full mutation (P=0.046). In the females, FMRP expression also correlated with the number of fragile X physical features (P=0.0003). Even modest deficits in FMRP result in some manifestations of fragile X syndrome. In this initial study of 53 males, FMRP expression testing had a very high positive predictive value (100%, confidence interval of 29-100%) for a nonretarded IQ among males with expression of FMRP in > or = 50% of lymphocytes (3 males), suggesting that FMRP expression may have potential as a prognostic indicator in males with fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331602

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  107 in total

Review 1.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

2.  Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening.

Authors:  Tri Indah Winarni; Agustini Utari; Farmaditya E P Mundhofir; Tzuhan Tong; Blythe Durbin-Johnson; Sultana M H Faradz; Flora Tassone
Journal:  Genet Test Mol Biomarkers       Date:  2011-10-11

Review 3.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

Review 6.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

7.  Psychiatric features in high-functioning adult brothers with fragile x spectrum disorders.

Authors:  Andrea Schneider; Andreea Seritan; Flora Tassone; Susan M Rivera; Randi Hagerman; David Hessl
Journal:  Prim Care Companion CNS Disord       Date:  2013

Review 8.  Molecular analysis of FMR1 alleles for fragile X syndrome diagnosis and patient stratification.

Authors:  Daman Kumari; Karen Usdin
Journal:  Expert Rev Mol Diagn       Date:  2020-02-18       Impact factor: 5.225

Review 9.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.

Authors:  Amy A Lightbody; Allan L Reiss
Journal:  Dev Disabil Res Rev       Date:  2009

10.  Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.

Authors:  P E Adams; J S Adams; D V Nguyen; D Hessl; J A Brunberg; F Tassone; W Zhang; K Koldewyn; S M Rivera; J Grigsby; L Zhang; C Decarli; P J Hagerman; R J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-04-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.